{"denomUnitsSelected":"Participants","description":"Blinatumomab PK will be evaluated by summarizing blinatumomab steady state concentrations and systemic clearance obtained from non-compartmental analysis. In addition, a population PK approach using a non-linear mixed effect model will also be used to assess blinatumomab PK. Exposure-response analyses will be performed to explore associations among blinatumomab exposure, relevant clinical covariates and clinical measures of safety and efficacy.","reportingStatus":"NOT_POSTED","timeFrame":"Days 2 and 14 of cycle 1","title":"Blinatumomab Pharmacokinetics (PK)","type":"OTHER_PRE_SPECIFIED"}